Cargando…
Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus
Antitumor efficacy of systemically administered oncolytic adenoviruses (OAdv) is limited due to diverse factors such as liver sequestration, neutralizing interactions in blood, elimination by the immune system, and physical barriers in tumors. It is therefore of clinical relevance to improve OAdv bi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525077/ https://www.ncbi.nlm.nih.gov/pubmed/28781596 http://dx.doi.org/10.1155/2017/3615729 |
_version_ | 1783252579962060800 |
---|---|
author | Moreno, R. Rojas, L. A. Villellas, Felip Vilardell Soriano, Vanessa Cervera García-Castro, J. Fajardo, C. A. Alemany, R. |
author_facet | Moreno, R. Rojas, L. A. Villellas, Felip Vilardell Soriano, Vanessa Cervera García-Castro, J. Fajardo, C. A. Alemany, R. |
author_sort | Moreno, R. |
collection | PubMed |
description | Antitumor efficacy of systemically administered oncolytic adenoviruses (OAdv) is limited due to diverse factors such as liver sequestration, neutralizing interactions in blood, elimination by the immune system, and physical barriers in tumors. It is therefore of clinical relevance to improve OAdv bioavailability and tumor delivery. Among the variety of tumor-targeting strategies, the use of stem cells and specifically bone marrow-derived mesenchymal stem cells (BM-MSCs) is of particular interest due to their tumor tropism and immunomodulatory properties. Nonetheless, the invasive methods to obtain these cells, the low number of MSCs present in the bone marrow, and their restricted in vitro expansion represent major obstacles for their use in cancer treatments, pointing out the necessity to identify an alternative source of MSCs. Here, we have evaluated the use of menstrual blood-derived mesenchymal stem cells (MenSCs) as cell carriers for regional delivery of an OAdv in the tumor. Our results indicate that MenSCs can be isolated without invasive methods, they have an increased proliferation rate compared to BM-MSCs, and they can be efficiently infected with different serotype 5-based capsid-modified adenoviruses, leading to viral replication and release. In addition, our in vivo studies confirmed the tumor-homing properties of MenSCs after regional administration. |
format | Online Article Text |
id | pubmed-5525077 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-55250772017-08-06 Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus Moreno, R. Rojas, L. A. Villellas, Felip Vilardell Soriano, Vanessa Cervera García-Castro, J. Fajardo, C. A. Alemany, R. Stem Cells Int Research Article Antitumor efficacy of systemically administered oncolytic adenoviruses (OAdv) is limited due to diverse factors such as liver sequestration, neutralizing interactions in blood, elimination by the immune system, and physical barriers in tumors. It is therefore of clinical relevance to improve OAdv bioavailability and tumor delivery. Among the variety of tumor-targeting strategies, the use of stem cells and specifically bone marrow-derived mesenchymal stem cells (BM-MSCs) is of particular interest due to their tumor tropism and immunomodulatory properties. Nonetheless, the invasive methods to obtain these cells, the low number of MSCs present in the bone marrow, and their restricted in vitro expansion represent major obstacles for their use in cancer treatments, pointing out the necessity to identify an alternative source of MSCs. Here, we have evaluated the use of menstrual blood-derived mesenchymal stem cells (MenSCs) as cell carriers for regional delivery of an OAdv in the tumor. Our results indicate that MenSCs can be isolated without invasive methods, they have an increased proliferation rate compared to BM-MSCs, and they can be efficiently infected with different serotype 5-based capsid-modified adenoviruses, leading to viral replication and release. In addition, our in vivo studies confirmed the tumor-homing properties of MenSCs after regional administration. Hindawi 2017 2017-07-11 /pmc/articles/PMC5525077/ /pubmed/28781596 http://dx.doi.org/10.1155/2017/3615729 Text en Copyright © 2017 R. Moreno et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Moreno, R. Rojas, L. A. Villellas, Felip Vilardell Soriano, Vanessa Cervera García-Castro, J. Fajardo, C. A. Alemany, R. Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus |
title | Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus |
title_full | Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus |
title_fullStr | Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus |
title_full_unstemmed | Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus |
title_short | Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus |
title_sort | human menstrual blood-derived mesenchymal stem cells as potential cell carriers for oncolytic adenovirus |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525077/ https://www.ncbi.nlm.nih.gov/pubmed/28781596 http://dx.doi.org/10.1155/2017/3615729 |
work_keys_str_mv | AT morenor humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus AT rojasla humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus AT villellasfelipvilardell humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus AT sorianovanessacervera humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus AT garciacastroj humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus AT fajardoca humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus AT alemanyr humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus |